| Authors: |
Budde LE; City of Hope Comprehensive Cancer Center, Duarte, CA, USA. ebudde@coh.org., Olszewski AJ; Brown University, Providence, RI, USA., Assouline S; Jewish General Hospital, McGill University, Montreal, Quebec, Canada., Lossos IS; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA., Diefenbach C; Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA., Kamdar M; University of Colorado, Aurora, CO, USA., Ghosh N; Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC, USA., Modi D; Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA., Sabry W; Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada., Naik S; Penn State Cancer Institute, Hershey, PA, USA., Mehta A; University of Alabama at Birmingham, Birmingham, AL, USA., Nakhoda SK; Fox Chase Cancer Center, Philadelphia, PA, USA., Smith SD; Fred Hutchinson Cancer Center, Seattle, WA, USA., Dorritie K; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA., Jia T; Roche (China) Holding Ltd, Shanghai, China., Pham S; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada., Huw LY; Genentech, Inc., South San Francisco, CA, USA., Jing J; Genentech, Inc., South San Francisco, CA, USA., Wu H; Genentech, Inc., South San Francisco, CA, USA., Ead WS; Genentech, Inc., South San Francisco, CA, USA., To I; Genentech, Inc., South San Francisco, CA, USA., Batlevi CL; Genentech, Inc., South San Francisco, CA, USA., Wei MC; Genentech, Inc., South San Francisco, CA, USA., Chavez JC; Moffitt Cancer Center, Tampa, FL, USA. Julio.C.Chavez@moffitt.org. |
